These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 25333487)

  • 21. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
    Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
    J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
    Keeton EK; McEachern K; Dillman KS; Palakurthi S; Cao Y; Grondine MR; Kaur S; Wang S; Chen Y; Wu A; Shen M; Gibbons FD; Lamb ML; Zheng X; Stone RM; Deangelo DJ; Platanias LC; Dakin LA; Chen H; Lyne PD; Huszar D
    Blood; 2014 Feb; 123(6):905-13. PubMed ID: 24363397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
    Koblish H; Li YL; Shin N; Hall L; Wang Q; Wang K; Covington M; Marando C; Bowman K; Boer J; Burke K; Wynn R; Margulis A; Reuther GW; Lambert QT; Dostalik Roman V; Zhang K; Feng H; Xue CB; Diamond S; Hollis G; Yeleswaram S; Yao W; Huber R; Vaddi K; Scherle P
    PLoS One; 2018; 13(6):e0199108. PubMed ID: 29927999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel 7-formyl-naphthyridyl-ureas derivatives as potential selective FGFR4 inhibitors: Design, synthesis, and biological activity studies.
    Sun C; Fang L; Zhang X; Gao P; Gou S
    Bioorg Med Chem; 2019 May; 27(10):1932-1941. PubMed ID: 30987781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting Antitumor Effect of Deoxypodophyllotoxin in NCI-H460 Tumor-Bearing Mice on the Basis of In Vitro Pharmacodynamics and a Physiologically Based Pharmacokinetic-Pharmacodynamic Model.
    Chen Y; Zhao K; Liu F; Li Y; Zhong Z; Hong S; Liu X; Liu L
    Drug Metab Dispos; 2018 Jun; 46(6):897-907. PubMed ID: 29618575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active and passive tumor targeting of a novel poorly soluble cyclin dependent kinase inhibitor, JNJ-7706621.
    Danhier F; Ucakar B; Magotteaux N; Brewster ME; Préat V
    Int J Pharm; 2010 Jun; 392(1-2):20-8. PubMed ID: 20226846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset.
    Padi SKR; Luevano LA; An N; Pandey R; Singh N; Song JH; Aster JC; Yu XZ; Mehrotra S; Kraft AS
    Oncotarget; 2017 May; 8(18):30199-30216. PubMed ID: 28415816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
    Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
    Drug Metab Dispos; 2015 Jan; 43(1):54-62. PubMed ID: 25349124
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.
    Zhang D; Zhang X; Ai J; Zhai Y; Liang Z; Wang Y; Chen Y; Li C; Zhao F; Jiang H; Geng M; Luo C; Liu H
    Bioorg Med Chem; 2013 Nov; 21(21):6804-20. PubMed ID: 23993328
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
    Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
    Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
    Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways.
    Meja K; Stengel C; Sellar R; Huszar D; Davies BR; Gale RE; Linch DC; Khwaja A
    Br J Haematol; 2014 Oct; 167(1):69-79. PubMed ID: 24975213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TGI-Simulator: a visual tool to support the preclinical phase of the drug discovery process by assessing in silico the effect of an anticancer drug.
    Terranova N; Magni P
    Comput Methods Programs Biomed; 2012 Feb; 105(2):162-74. PubMed ID: 22005012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NSC746364, NSC746365, and NSC746366: the spectra of cytotoxicity and molecular correlates of response to telomerase activity.
    Huang HS; Huang KF; Lee CC; Chen CL; Li CL; Lin JJ
    Anticancer Drugs; 2010 Feb; 21(2):169-80. PubMed ID: 19884821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of two pharmacodynamic transduction models for the analysis of tumor therapeutic responses in model systems.
    Yang J; Mager DE; Straubinger RM
    AAPS J; 2010 Mar; 12(1):1-10. PubMed ID: 19902363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
    Yadav AK; Kumar V; Bailey DB; Jang BC
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
    Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
    Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic-pharmacodynamic modeling of the antitumor effect of TM208 and EGFR-TKI resistance in human breast cancer xenograft mice.
    Ji XW; Ji SM; Li RT; Wu KH; Zhu X; Lu W; Zhou TY
    Acta Pharmacol Sin; 2016 Jun; 37(6):825-33. PubMed ID: 27133303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bridging the gap between preclinical and clinical studies using pharmacokinetic-pharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor.
    Wong H; Vernillet L; Peterson A; Ware JA; Lee L; Martini JF; Yu P; Li C; Del Rosario G; Choo EF; Hoeflich KP; Shi Y; Aftab BT; Aoyama R; Lam ST; Belvin M; Prescott J
    Clin Cancer Res; 2012 Jun; 18(11):3090-9. PubMed ID: 22496205
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PIM kinase inhibitor AZD1208 for treatment of MYC-driven prostate cancer.
    Kirschner AN; Wang J; van der Meer R; Anderson PD; Franco-Coronel OE; Kushner MH; Everett JH; Hameed O; Keeton EK; Ahdesmaki M; Grosskurth SE; Huszar D; Abdulkadir SA
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25505253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.